Studies in patients with T1D have shown that insulin degludec reduces the risk of nocturnal hypoglycemia by 25% compared to insulin glargine, whereas the incidence of daytime hypoglycemia was comparable between the two groups [46]. Here, INS is linked to type 1 diabetes mellitus.